替尔泊肽心血管事件风险评估:一项预先设定的荟萃分析
该预先设定的心血管荟萃分析纳入替尔泊肽2型糖尿病临床开发项目SURPASS中全部七项至少26周的随机对照试验,比较替尔泊肽组与对照组首次确诊四组分主要不良心血管事件(MACE-4)的时间。结果显示替尔泊肽相比对照组未增加2型糖尿病参与者的主要心血管事件风险,MACE-4的HR为0.80(95%CI 0.57-1.11)。
要点
- 替尔泊肽组与对照组MACE-4的HR为0.80(95%CI 0.57-1.11)。
- 心血管死亡HR为0.90(95%CI 0.50-1.61),全因死亡HR为0.80(95%CI 0.51-1.25)。
- 替尔泊肽未增加2型糖尿病参与者的主要心血管事件风险。
核心结论
- 替尔泊肽相比对照组未增加2型糖尿病参与者的主要心血管事件风险。
研究设计与样本
- 预先设定的心血管荟萃分析纳入替尔泊肽2型糖尿病临床开发项目SURPASS中全部七项持续时间至少26周的随机对照试验。
- 分析数据来自4887名接受替尔泊肽治疗的参与者和2328名对照参与者。
- 采用分层Cox比例风险模型估计风险比(HR)和置信区间(CI),以治疗为固定效应、试验水平心血管风险为分层因素。
主要发现
- 总体共有142名参与者至少发生一次MACE-4事件,其中109名来自高心血管风险试验,33名来自六项低心血管风险试验。
- 替尔泊肽组相比对照组的MACE-4的HR为0.80(95%CI 0.57-1.11)。
- 心血管死亡的HR为0.90(95%CI 0.50-1.61),全因死亡的HR为0.80(95%CI 0.51-1.25)。
- 未观察到任何亚组存在效应修饰的证据,尽管高心血管风险参与者的证据更强。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist and is under development for the treatment of type 2 diabetes (T2D) and obesity. Its association with cardiovascular outcomes requires evaluation. This pre-specified cardiovascular meta-analysis included all seven randomized controlled trials with a duration of at least 26 weeks from the tirzepatide T2D clinical development program, SURPASS. The pre-specified primary objective of this meta-analysis was the comparison of the time to first occurrence of confirmed four-component major adverse cardiovascular events (MACE-4; cardiovascular death, myocardial infarction, stroke and hospitalized unstable angina) between pooled tirzepatide groups and control groups. A stratified Cox proportional hazards model, with treatment as a fixed effect and trial-level cardiovascular risk as the stratification factor, was used for the estimation of hazard ratios (HRs) and confidence intervals (CIs) comparing tirzepatide to control. Data from 4,887 participants treated with tirzepatide and 2,328 control participants were analyzed. Overall, 142 participants, 109 from the trial with high cardiovascular risk and 33 from the six trials with lower cardiovascular risk, had at least one MACE-4 event. The HRs comparing tirzepatide versus controls were 0.80 (95% CI, 0.57-1.11) for MACE-4; 0.90 (95% CI, 0.50-1.61) for cardiovascular death; and 0.80 (95% CI, 0.51-1.25) for all-cause death. No evidence of effect modifications was observed for any subgroups, although the evidence was stronger for participants with high cardiovascular risk. Tirzepatide did not increase the risk of major cardiovascular events in participants with T2D versus controls.
引用
- Sattar N, McGuire DK, Pavo I, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022. PMID: 35210595. doi:10.1038/s41591-022-01707-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。